The Sage Group Advises Cancer Prevention Pharmaceuticals on Transaction for Orphan Drug

New York and London, July 28, 2021 - The Sage Group has announced that it advised Cancer Prevention Pharmaceuticals, Inc. (CPP), resulting in the North American licensing of its fixed dose combination drug Flynpovi for the treatment of familial adenomatous polyposis (FAP), an orphan disease which affects 25 to 30,000 individuals in the US and for which the product has received Fast Track and Orphan Drug designation

Neither the identity of the licensee nor the terms of the license is being publicly disclosed, but the terms call for an initial payment, regulatory milestone payments and royalties. "

About Cancer Prevention Pharmaceuticals

Cancer Prevention Pharmaceuticals is a clinical stage company developing therapeutics to reduce the risk and recurrence of cancer and rare diseases.

CPP’s innovative technology addresses polyamine metabolism, immune regulation and inflammation to reduce cancer risk and impact other diseases.

These two processes have long been implicated in cancer development but never successfully utilized together to exploit and treat cancer precursors until now.